The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0165-5728(03)00154-1 | DOI Listing |
Publication Analysis
Top Keywords
multiple sclerosis
8
leptin
6
patients
5
leptin marker
4
marker multiple
4
sclerosis activity
4
activity patients
4
patients treated
4
treated interferon-beta
4
interferon-beta role
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!